[go: up one dir, main page]

BRPI0516314A - uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv - Google Patents

uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv

Info

Publication number
BRPI0516314A
BRPI0516314A BRPI0516314-5A BRPI0516314A BRPI0516314A BR PI0516314 A BRPI0516314 A BR PI0516314A BR PI0516314 A BRPI0516314 A BR PI0516314A BR PI0516314 A BRPI0516314 A BR PI0516314A
Authority
BR
Brazil
Prior art keywords
hiv
treatment
whole
infected individual
chronically infected
Prior art date
Application number
BRPI0516314-5A
Other languages
English (en)
Inventor
Jean-Marie Andrieu
Louis Wei-Lu
Original Assignee
Biovaxim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovaxim Ltd filed Critical Biovaxim Ltd
Publication of BRPI0516314A publication Critical patent/BRPI0516314A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

USO DE HIV INTEIRO E MéTODO DE TRATAMENTO DE UM INDIVìDUO CRONICAMENTE INFECTADO COM HIV. Um HIV inteiro inativado de um subtipo particular é utilizado para preparar vacinas e composições farmacêuticas que contêm vacinas. As vacinas podem ser usadas para tratar indivíduos cronicamente infectados com HIV, por indução de uma resposta imune celular protetora nos indivíduos contra o mesmo subtipo HIV usado para produzir a vacina.
BRPI0516314-5A 2004-10-04 2005-10-04 uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv BRPI0516314A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61572904P 2004-10-04 2004-10-04
US11/243,094 US20060093623A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with HIV infection
PCT/IB2005/003384 WO2006038124A1 (en) 2004-10-04 2005-10-04 Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection

Publications (1)

Publication Number Publication Date
BRPI0516314A true BRPI0516314A (pt) 2008-09-02

Family

ID=35695555

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516314-5A BRPI0516314A (pt) 2004-10-04 2005-10-04 uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv

Country Status (14)

Country Link
US (1) US20060093623A1 (pt)
EP (1) EP1797175B1 (pt)
JP (1) JP2008515795A (pt)
CN (1) CN101056977B (pt)
AT (1) ATE401392T1 (pt)
AU (1) AU2005290930B2 (pt)
BR (1) BRPI0516314A (pt)
CA (1) CA2582426A1 (pt)
DE (1) DE602005008264D1 (pt)
ES (1) ES2310848T3 (pt)
IL (1) IL182440A (pt)
MX (1) MX2007004028A (pt)
RU (1) RU2396346C2 (pt)
WO (1) WO2006038124A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558933T3 (es) 2009-01-29 2016-02-09 Michel Vandevelde Composición de vacuna a base de un virus que presenta una proteína con uno o varios restos de dedo de zinc, su procedimiento de preparación y su utilización
WO2010096831A1 (en) * 2009-02-23 2010-08-26 Candace Pert Rapid infectious virus assay
BR112013025481B8 (pt) * 2011-04-06 2022-11-08 Univ Paris Descartes Composições farmacêuticas, uso destas e kits para prevenir e/ou tratar uma doença por hiv em humanos
IN2014DN07961A (pt) * 2012-03-02 2015-05-01 Esteve Labor Dr
EP2821082A1 (en) * 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
PE20191842A1 (es) 2017-05-08 2019-12-31 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus
TW202523847A (zh) 2019-05-30 2025-06-16 美商磨石生物公司 經修飾之腺病毒
WO2021003348A1 (en) * 2019-07-02 2021-01-07 Gritstone Oncology, Inc. Hiv antigens and mhc complexes
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764938B2 (en) * 1998-02-13 2003-09-04 Adan Rios Method for the development of an HIV vaccine
US6828460B2 (en) * 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
WO2001055177A2 (en) * 2000-01-28 2001-08-02 Statens Serum Institut Methods to identify ctl epitopes of hiv
WO2002072140A2 (en) * 2001-02-27 2002-09-19 Institut Pasteur Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
EP1490396A4 (en) * 2001-03-01 2006-04-19 Us Gov Health & Human Serv IMMUNOGENIC HIV PEPTIDES AS REAGENTS AND AS VACCINES
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
US20040009194A1 (en) * 2002-06-21 2004-01-15 Jean-Marie Andrieu Methods, and compositions for a therapeutic antigen presenting cell vaccine for treatment of immunodeficiency virus
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
AU2003302504B2 (en) * 2002-12-04 2007-03-08 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
US7556814B2 (en) * 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane

Also Published As

Publication number Publication date
EP1797175B1 (en) 2008-07-16
RU2007115549A (ru) 2008-11-10
EP1797175A1 (en) 2007-06-20
JP2008515795A (ja) 2008-05-15
ES2310848T3 (es) 2009-01-16
AU2005290930B2 (en) 2010-12-16
RU2396346C2 (ru) 2010-08-10
DE602005008264D1 (de) 2008-08-28
US20060093623A1 (en) 2006-05-04
AU2005290930A1 (en) 2006-04-13
IL182440A (en) 2011-01-31
WO2006038124A1 (en) 2006-04-13
ATE401392T1 (de) 2008-08-15
CN101056977B (zh) 2013-01-30
CA2582426A1 (en) 2006-04-13
IL182440A0 (en) 2007-07-24
CN101056977A (zh) 2007-10-17
MX2007004028A (es) 2007-09-11

Similar Documents

Publication Publication Date Title
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
MX2018009917A (es) Vacuna contra el virus del zika.
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
ATE452900T1 (de) Impfstoff gegen das west-nile-virus
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
BR112022022859A2 (pt) Vacinas contra sars-cov-2
UY36394A (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso.
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
AR039982A1 (es) Composicion vacunal contra las alergias, metodo para su obtencion y empleo en el tratamiento de las mismas
AR106057A1 (es) Composición con efecto antiviral, composición farmacéutica
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
BR112022007253A2 (pt) Vacinas contra o vírus influenza e usos das mesmas
BRPI0414442A (pt) composições de vacina de dna e métodos de utilização

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.